Incyte Adds Dr. Pimple Popper to Atopic Dermatitis Initiative

Incyte

Incyte is expanding its educational initiative called Moments of Clarity.¹ The program focuses on atopic dermatitis and various ways of treating or relieving the symptoms. The program initially launched last year with Mandy Moore serving as its spokesperson. The expanded program has added Dr. Sandra Lee, who is better known for her online and media persona Dr. Pimple Popper.

The program features patients telling their stories and promotes the use of Opzelura cream, which is produced by Incyte.

In a press release, Dr. Lee said, “While many people know me as a dermatologist from my TV show, most probably don’t know that I live with eczema and have struggled with symptoms like persistent itch and skin inflammation throughout my life. I started using Opzelura, a non-steroidal topical option, to treat my eczema flares, which helped alleviate some of my worst symptoms like itch. In the pivotal clinical trial for mild to moderate AD, 54% of patients had clear to almost clear skin at 8 weeks and 52% of patients had a significant reduction in their itch, compared to 15% of patients who used a cream that did not contain medication. I partnered with Incyte on their Moments of Clarity program to share my story and to empower others to seek out a treatment that is right for them.”

Incyte executive vice president and general manager of US Dermatology Matteo Trotta added, “We understand the impact eczema can have on daily life, which furthers the need for patients to find a treatment to address their individual symptoms. We are proud to elevate the patient voice and share the real, lived experience with Opzelura as part of our commitment to patients and to providing a treatment that can help address some of the most burdensome symptoms of AD. Our hope is that the Moments of Clarity program helps those living with eczema connect with others and inspires them to have conversations with their doctor.”

In September of this year, Incyte announced that it would be presenting data from across its dermatology portfolio at the European Academy of Dermatology and Venereology 2024 Congress, which occurred on September 25-28 in Amsterdam.²

In a press release issued at the time, Incyte’s president and head of research and development Pablo J. Cagnoni, MD, said, “We’re excited to present five late-breaking oral presentations at this year’s congress, featuring data that could further expand treatment options for those living with immune-mediated dermatologic conditions, including vitiligo, atopic dermatitis, hidradenitis suppurativa and prurigo nodularis. The data highlight our ongoing efforts to evaluate the efficacy and safety of ruxolitinib cream in new patient populations, as well as deepen our understanding of povorcitinib in patients impacted by debilitating immune-mediated dermatologic conditions.”

Also in September, Incyte announced new early clinical data for CDK2 inhibitor INCB123667.³

At the time, Cagnoni said in a press release, “The early-stage clinical activity of INCB123667 represents an exciting and promising breakthrough for patients with ovarian cancer. We believe this novel CDK2 inhibitor has the potential to be a foundational treatment for platinum-resistant ovarian cancer, offering a new and differentiated treatment for patients who currently have limited treatment options. We look forward to advancing the development of INCB123667 for the treatment of patients with ovarian cancer both as a single agent and in combination.”

Sources

1. Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program. Incyte. October 10, 2024. Accessed October 16, 2024. https://investor.incyte.com/news-releases/news-release-details/incyte-furthers-commitment-people-living-atopic-dermatitis
2. Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress. Incyte. September 25, 2024. Accessed October 16, 2024. https://investor.incyte.com/news-releases/news-release-details/multiple-late-breaking-data-presentations-incytes-dermatology
3. Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer. Incyte. September 14, 2024. Accessed October 16, 2024. https://investor.incyte.com/news-releases/news-release-details/incytes-cdk2-inhibitor-incb123667-shows-promising-evidence